Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Taking vitamin D and calcium supplements reduces the risk of hip fractures by about one sixth, but taking vitamin D alone does not, according to a new study from the Nuffield Department of Population Health (NDPH) at the University of Oxford.

None © Shutterstock

The research was led by Research Fellow Dr Pang Yao and Robert Clarke, Professor of Epidemiology and Public Health Medicine, at NDPH. The researchers combined findings from 11 observational studies of vitamin D blood levels and the associated risk of fracture with more than 39,000 participants, 6 trials of combined vitamin D and calcium treatment with more than 49,000 participants, and 11 trials of vitamin D supplements alone with 34,000 participants. The research has been published in JAMA Network Open.

The observational studies showed that low blood levels of vitamin D are associated with higher risks of fracture, but the trial results have been inconclusive. The trials of vitamin D plus calcium showed a small reduction in the risk of fractures. In people over the age of 80 years, and those living in institutions however, the effects were greater, with the risk of hip fracture lowered by almost one-third. While the trials of vitamin D alone did not show a reduction in the risk of fracture, these trials included some large studies of very high annual doses of vitamin D which increased the risk of fracture, and few of the trials tested doses of vitamin D high enough to raise the blood levels of vitamin D sufficiently to reduce the fracture risk.

Read more (University of Oxford)

Similar stories

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Oxford University and partners win government funding to evaluate Paige Prostate Cancer Detection System

A prostate cancer detection software system to help pathologists quickly identify suspicious areas of tissue, developed by Paige, will be investigated in a multicentre clinical study led by Oxford University as part of a successful NHSx Artificial Intelligence Health and Care Award application.

Treating Needle Fears May Reduce COVID-19 Vaccine Hesitancy Rates by 10%

A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.